SCHEMBL220656

SCHEMBL220656

CC(C)N1CCC(N(CC(=O)N2CCOCC2)S(=O)(=O)CCNC(=O)c2ccc(Cl)s2)CC1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
F10 P00742 15/20 0.59
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
F2 P00734 6/20 0.39
KLKB1 P03952 3/20 0.39
PLAT P00750 1/20 0.39
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222025 0.91 F10 (0.59) F10LMNAF2KLKB1PLAT
SCHEMBL3874943 0.87 F10 (0.43) F10LMNAF2KLKB1PLAT
SCHEMBL219872 0.86 F10 (0.63) F10MAPK1SMN1; SMN2
SCHEMBL219860 0.84 F10 (0.65) F10LMNATSHRMAPK1KMT2A
SCHEMBL219743 0.82 F10 (0.63) F10LMNAMAPK1KMT2ASMN1; SMN2
SCHEMBL221417 0.82 F10 (0.63) F10MAPK1ALDH1A1SMN1; SMN2
SCHEMBL221251 0.82 F10 (0.63) F10MAPK1SMN1; SMN2
SCHEMBL221193 0.82 F10 (0.69) F10LMNAMAPK1KMT2ASMN1; SMN2
SCHEMBL220506 0.81 F10 (0.55) F10F2MAPK1MEN1KMT2A
SCHEMBL221616 0.80 F10 (0.60) F10F2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 US claimed
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 US disclosed